AP
LEGN icon

Aspect Partners’s Legend Biotech LEGN Stock Holding History

Aspect Partners’s Portfolio LEGN Stock Details LEGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.62K Buy
160
+9
+6% +$243 ﹤0.01% 431
2026
Q1 		$2.73K Buy
151
+15
+11% +$286 ﹤0.01% 441
2025
Q4 		$2.96K Buy
+136
New +$3.9K ﹤0.01% 459

Other funds holding LEGN

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
ELI
Empire Life Investments Toronto, Ontario, Canada $1.79B AUM 38.49% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
CPC
Cookson Peirce & Co Pittsburgh, Pennsylvania $3.04B AUM 94.11% 1-Year Est. Return
EFMH
E Fund Management (HK) Central, Hong Kong $302M AUM 64.42% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
TPSF
Texas Permanent School Fund Austin, Texas $2.26B AUM 7.02% 1-Year Est. Return
YMRC
Yorktown Management & Research Company Forest, Virginia $163M AUM 68.53% 1-Year Est. Return
CUAMC
China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return

Aspect Partners's LEGN Position: Q2 2026 in Review

Aspect Partners increased its Legend Biotech (LEGN) stake by 6% in Q2 2026, buying an estimated $243 and bringing the position to 160 shares worth $4.62K. The position accounts for ﹤0.01% of the portfolio, ranked #431.

Aspect Partners first reported a position in LEGN in Q4 2025 and has held it in 3 quarters since. 31 funds tracked by Wall St. Rank hold LEGN as of Q2 2026.

  • Aspect Partners held 160 shares of Legend Biotech worth $4.62K as of Q2 2026.
  • Aspect Partners bought 9 Legend Biotech shares in Q2 2026, an estimated $243.
  • Legend Biotech made up ﹤0.01% of Aspect Partners's portfolio in Q2 2026, its #431 holding.
  • Aspect Partners first reported a position in Legend Biotech in Q4 2025 and has held it in 3 quarters since.
  • 31 funds tracked by Wall St. Rank held Legend Biotech as of Q2 2026.

Based on Aspect Partners's 13F filing for Q2 2026, filed 16 Jul 2026.